Source link : https://www.newshealth.biz/health-news/hemophilia-b-gene-therapy-shows-promise/
TOPLINE: Fidanacogene elaparvovec gene therapy reduced the annualized bleeding rate by 71% in patients with hemophilia B. Factor IX activity levels were sustained at 26.9% at 15 months post-treatment. METHODOLOGY: A phase 3 open-label study was conducted involving 45 men aged 18-65 years with hemophilia B and a factor IX level ≤ 2%. Participants received […]
Author : News Health
Publish date : 2024-10-31 12:19:23
Copyright for syndicated content belongs to the linked Source.
